A simple method for improving the specificity of anti-methyl histone antibodies by Connor, Caroline M. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Student Publications Graduate School of Biomedical Sciences 
2010-07-01 
A simple method for improving the specificity of anti-methyl 
histone antibodies 
Caroline M. Connor 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_sp 
 Part of the Medicine and Health Sciences Commons, and the Neuroscience and Neurobiology 
Commons 
Repository Citation 
Connor CM, Cheung I, Simon A, Jakovcevski M, Weng Z, Akbarian S. (2010). A simple method for 
improving the specificity of anti-methyl histone antibodies. GSBS Student Publications. https://doi.org/
10.4161/epi.5.5.11874. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/1690 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Student 
Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Epigenetics 5:5, 392-395; July 1, 2010; © 2010 Landes Bioscience
 BriEf rEport
392 Epigenetics Volume 5 issue 5
*Correspondence to: Schahram Akbarian; Email: schahram.akbarian@umassmed.edu
Submitted: 02/17/10; Accepted: 03/25/10
Previously published online: www.landesbioscience.com/journals/epigenetics/article/11874
Chromatin-immunoprecipitation (ChIP) with site- and modifi-
cation-specific anti-histone antibodies is a key approach in the 
field of epigenetics. Enrichment of a given histone modification 
can subsequently be measured at a defined gene locus with PCR 
(ChIP-PCR) or, more recently, on a genome-wide scale with 
massively parallel sequencing (ChIP-Seq).1 In particular, meth-
ylation of specific histone lysine residues—including H3K4, 
H3K36, H3K79; H3K9, H3K27 and H4K20—represents 
one of the most highly regulated types of chromatin modifica-
tions.2 Importantly, these lysine side chains can carry up to three 
methyl groups, and their mono-, di- and trimethylated forms are 
differentially localized within the genome and exert distinct 
effects on transcription. In the case of H3K4, the trimethyl-
ated form (H3K4me3) is primarily associated with transcription 
start sites, while the monomethylated form, H3K4me1, defines 
enhancer sequences and other regulatory elements further 
removed from proximal promoters.3,4 Finally, the dimethyl mark, 
H3K4me2, appears to be more broadly distributed with open 
chromatin primarily around the 5' portion of genes.3,4 Given that 
the functional effects of each of the three marks is very different, 
it is critical to perform ChIP with antibodies with selective recog-
nition for either the mono-, di- or trimethylated forms.
Many of the commercially available modification-specific 
antibodies are polyclonal, reflecting a perception of the field that 
these preparations provide better signal-to-noise as compared to 
monoclonals. However, we noticed that—while most antibod-
ies are highly selective for a specific histone lysine residue—there 
can be considerable lot-to-lot variability in me1/2/3 specificity. In 
particular, cross-reactivity for the H3K4me2 mark was frequently 
detected with anti-H3K4me3 antibodies (Fig. 1A and B). This 
represents a serious problem, as each of the different methylation 
marks confers specific effects on gene transcription.2,5 Numerous 
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methods to improve antibody specificity, including affinity puri-
fication and pre-incubation with non-specific immunoglobulin, 
already exist. However, these methods are not directed towards 
removal of remaining antibodies with non-specific immunoreac-
tivity for a particular antigen, in our case, me2. Here, we describe 
a simple, but effective, procedure for improving antibody speci-
ficity for the H3K4me3 mark.
We describe two slightly different, equally effective protocols 
for improvement of antibody specificity, both of which include 
pre-incubation of antibody with peptide of the histone modifica-
tion for which the antibody demonstrates non-specific immuno-
reactivity. In the first method, 4 µg rabbit polyclonal antibody 
against trimethylated histone H3 lysine 4 (H3K4me3; Millipore, 
07-473) was incubated with 9 µg of dimethylated H3K4 
peptide (H3K4me2; Abcam, ab7768) spotted onto a 0.5 cm2 
piece of nitrocellulose membrane in 500 µl 1x FSB (frozen 
storage buffer; 5 mM EDTA, 20 mM Tris-HCl and 50 mM 
NaCl, pH 7.5) for 1 hour at room temperature. The synthetic 
peptide was derived from amino acids 1–100 of human histone 
H3 (martkqtarkstggkaprkqlatkaarksapatggvkkphryrpgtvalreir-
ryqkstellirklpfqrlvreiaqdf ktdlrfqssavmalqeaceay), dimethyl-
ated at lysine residue 4. In the second method, the H3K4me2 
peptide was pipetted directly into the antibody solution, incu-
bated for 1 h at room temperature, and the resulting antibody-
peptide solution used for ChIP. To assess the immunoreactivity 
of the anti-H3K4me3 antibody for the mono-, di- and trimeth-
ylated forms of H3K4, we performed dot blots in which pep-
tide for each of the three forms of H3K4 were spotted onto a 
membrane and allowed to dry; subsequently, membranes were 
incubated with anti-H3K4me3 antibody. As shown in Figure 1A 
and B, the untreated anti-H3K4me3 antibody demonstrates sig-
nificant non-specific immunoreactivity for the dimethyl H3K4 
Antibodies differentiating between the mono-, di- and trimethylated forms of specific histone lysine residues are a 
critical tool in epigenome research, but show variable specificity, potentially limiting comparisons across studies and 
between samples. Using trimethyl histone H3 lysine 4 (H3K4me3)—a mark enriched at transcription start sites (tSS) of 
active genes—as an example, we describe how simple co-incubation with synthetic peptide of the K4me2 modification 
leads to increased specificity for K4me3 and a much sharper peak distribution proximal to tSS following chromatin 
immunoprecipitation and massively parallel sequencing (Chip-Seq).
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Figure 1. preincubation of anti-H3K4me3 antibody with H3K4me2 peptide reduces nonspecific immunoreactivity and improves performance during 
Chip. (A and B) preincubation of anti-H3K4me3 antibody with increasing amounts of H3K4me2 peptide on membrane (A) or in solution (B) decreases 
immunoreactivity of the antibody for this modification on dot blot. (C and D) Chip performed with anti-H3K3me3 antibody pre-incubated with 15 µg 
H3K4me2 peptide in solution results in significantly more sequences <1 kb from tSS compared to untreated antibody (C). there was no significant 
difference at <2 kb from tSS (D). (E and f) An anti-H3K4me3 antibody which demonstrates low immunoreactivity for H3K4me2 peptide on dot blot 
(“Antibody 2”) results in significantly more sequences <1 kb (E) and <2 kb (f) from tSS post-Chip compared to an anti-H3K4me3 antibody with high 
immunoreactivity for H3K4me2 peptide on dot blot (“Antibody 1”).
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peptide. However, pre-incubation of the antibody with 
H3K4me2 peptide visibly decreases this nonspecific 
immunoreactivity without altering immunoreactivity 
for its intended antigen.
To test whether this increased specificity in immuno-
reactivity translated to improved specificity of DNA 
sequences pulled down during chromatin immuno- 
precipitation, we performed ChIP on human and mouse 
chromatin isolated from brain tissue using untreated or 
pre-incubated anti-H3K4me3 antibody using a stan-
dard protocol for native ChIP.6 Subsequently, immu-
noprecipitated DNA was processed for deep sequencing 
by ligating the Genomic Adaptor Oligo Mix (Illumina) 
to fragments,  followed by PCR amplification and gel 
purification of fragments around 250 base pairs.
As an initial assessment of the DNA immuno-
precipitated by treated versus untreated antibody, a 
fraction of the library was subcloned into the pDrive 
vector (Qiagen) and transformed into DH5α cells 
(Invitrogen). Twenty clones were sequenced, aligned 
with the mouse or human genome, and their proxim-
ity to TSS determined. As shown in Figure 1C, anti-
H3K4me3 antibody pre-incubated with H3K4me2 
peptide pulled down significantly more sequences 
less than 1 kb from annotated TSS as compared to 
untreated antibody (41% versus 20%; p = 0.031). This 
is consistent with the literature showing that trimethyl-
ated H3K4 is highly localized around TSS of actively 
transcribed genes.4
Extending the relationship between specificity 
of immunoreactivity on dot blot to performance of 
antibody during ChIP, we compared sequences from 
human brain immunoprecipitated with two commer-
cially available anti-H3K4me3 antibodies: one of which 
demonstrated significant non-specific immunoreactiv-
ity for H3K4me2 peptide on dot blot (“Antibody 1”; 
Abcam, ab8580) and the other of which exhibited fairly 
specific immunoreactivity for H3K4me3 (“Antibody 2”; 
Upstate, 07-473). Figure 1E and F show that Antibody 
2 pulled down significantly more sequences <1 kb from 
TSS (55% versus 27%; p = 0.0018) and <2 kb from 
TSS (60% versus 31%; p = 0.001). It must be noted 
that non-specific immunoreactivity for any given anti-
body can vary significantly from lot-to-lot, independent 
of the manufacturer.
Next, we asked whether pre-incubation of anti-
H3K4me3 antibody with H3K4me2 peptide led to 
increased percentage of sequences in close proxim-
ity to annotated TSS genome-wide. Four mouse 
H3K4me3 ChIP libraries were deep sequenced by 
an Illumina Genome Analyzer (GA II) and genomic 
regions containing a significantly large number of 
reads, called peaks, were detected with the MACS 
software.7 Data from each sample were normalized for 
sequencing depth and the distribution of H3K4me3 
peaks relative to TSS was determined. The percentages 
Figure 2. Chip-Seq performed with pre-incubated anti-H3K4me3 antibody results 
in a greater percentage of proximal peaks. (A) Chip performed with pre-incubated 
anti-H3K4me3 antibody results in a greater percentage of proximal peaks (∼85% 
of total peaks) compared to untreated antibody (∼72% of total peaks). (B) the two 
Chip samples prepared with pre-incubated anti-H3K4me3 antibody show a higher 
proportion of peaks in close proximity to tSS and a proportional decrease in those 
distal to tSS. (C) the two Chip samples prepared with pre-incubated anti-H3K4me3 
antibody demonstrate a higher proportion of sequence tags directly downstream 
from tSS compared to samples prepared with untreated antibody. in addition, the 
number of tags in the pre-incubated samples decline more quickly with increasing 
distance from tSS.
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compared with the two samples prepared with untreated anti-
body. As previously reported,4,8 the periodic behavior of the 
aggregation plot indicates well-positioned nucleosomes.
In summary, we show that pre-incubation of commer-
cially available anti-H3K4me3 antibody with a peptide of the 
H3K4me2 epitope results in significant improvement in antibody 
specificity and much sharper peaks around TSS genome-wide. 
These clean-up procedures are particularly important given that 
the three forms of methylated H3K4 possess different functions 
with regards to regulation of transcription.
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of proximal (<2 kb from TSS), medial (2–5 kb) and distal 
(>10 kb) peaks are shown in Figure 2A. It is apparent that the two 
samples prepared with H3K4me3 antibody pre-incubated with 
15 µg H3K4me2 peptide in solution contain a higher percentage 
of proximal peaks (∼85%) compared to samples prepared with 
untreated antibody (∼72%). The distribution of peaks relative to 
TSS is shown in Figure 2B. We performed Wilcoxon rank sum 
tests on the distances of the peaks to the nearest TSS between 
samples. Peaks in the two samples prepared with peptide (ChIP 
3 and 4) were significantly closer to a TSS than peaks in the two 
samples prepared without peptide (ChIP 1 and 2): p-value <8.9 x 
10-36 for all four pair-wise comparisons. Next, in order to charac-
terize the detailed distribution of sequence tags around TSS, we 
used the GSA software8 to produce an aggregation plot, shown 
in Figure 2C. The two samples prepared with pre-incubated 
antibody have much higher numbers of tags immediately down-
stream from the TSS, while a faster decline further downstream, 
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